17/10/2022 (Agence Europe) – On 13 October, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the authorisation of the live inactivated tetravalent vaccine developed by the Japanese pharmaceutical company Takeda Pharmaceutical to prevent the disease caused by serotypes 1, 2, 3 and 4 of the dengue virus. The vaccine can be given from the age of 4 years. The EMA states that, for the first time, the CHMP is...